Lactose Monohydrate

Lactose monohydrate, a common sugar found in milk, has been widely used as a placebo in clinical trials. This article explores its application in various studies, particularly those investigating treatments for COVID-19, high altitude headaches, and nicotine-seeking behavior. By examining these trials, we can better understand how lactose monohydrate serves as a control substance in medical research, helping scientists evaluate the effectiveness of new treatments and medications.

Table of Contents

What is Lactose Monohydrate?

Lactose monohydrate is a form of sugar commonly found in milk and dairy products. In medical research, it is often used as an inactive ingredient or placebo in clinical trials. A placebo is a substance that has no therapeutic effect and is used as a control in testing new drugs or treatments.[1]

Uses in Clinical Trials

Lactose monohydrate is not used to treat any specific diseases. Instead, it serves important purposes in clinical research:

  • Placebo Control: In a study on COVID-19 treatment, lactose monohydrate was used as a placebo to compare against the active drug amantadine. Participants in the control group received lactose monohydrate capsules that looked identical to the active treatment.[1]
  • Blinding in Studies: In a study on nicotine-seeking behavior in smokers, lactose monohydrate was used as a placebo to maintain the double-blind nature of the experiment. This means neither the participants nor the researchers knew who was receiving the active treatment or the placebo.[2]

Role as a Placebo in Research

Lactose monohydrate plays a crucial role in clinical trials as a placebo:

  • Comparison: It allows researchers to compare the effects of an active treatment against no treatment, while controlling for the psychological effects of taking a medication.[1]
  • Mimicking Active Treatment: In the COVID-19 study, lactose monohydrate was encapsulated to look identical to the active treatment (amantadine). This helps maintain the integrity of the study by ensuring participants don’t know which treatment they’re receiving.[1]
  • Dosage Matching: In the smoking behavior study, the lactose monohydrate doses were matched in weight to the active treatments (54mg and 10mg) to further ensure blinding.[2]

Safety and Side Effects

Lactose monohydrate is generally considered safe for most people when used as a placebo in clinical trials. However, there are some considerations:

  • Lactose Intolerance: People with lactose intolerance may experience digestive symptoms if they consume lactose monohydrate. These could include bloating, gas, or diarrhea.
  • Allergies: Individuals with milk allergies should be cautious, as lactose monohydrate is derived from milk.
  • Minimal Risk: As an inactive ingredient, lactose monohydrate is not expected to cause significant side effects in most people when used in small amounts for research purposes.

Considerations for Patients

If you’re considering participating in a clinical trial that may use lactose monohydrate as a placebo, keep these points in mind:

  • Inform Researchers: Always inform the research team about any allergies or intolerances you have, including lactose intolerance or milk allergies.
  • Understanding Placebos: Remember that receiving a placebo like lactose monohydrate is an important part of clinical research. It helps researchers determine the true effects of the treatment being studied.[1]
  • Blinding: In many studies, neither you nor the researchers will know whether you’re receiving the active treatment or the placebo. This is called “double-blinding” and helps prevent bias in the study results.[2]
  • No Therapeutic Benefit: Lactose monohydrate, when used as a placebo, is not intended to provide any medical benefit. Its purpose is purely for comparison in research studies.
Trial Focus Use of Lactose Monohydrate Comparison Drug Key Outcomes Measured
COVID-19 Treatment Placebo control Amantadine Clinical status, hospitalization, mechanical ventilation, adverse events
High Altitude Headache Placebo control Acetazolamide Optic nerve sheath diameter, headache severity, blood oxygen saturation
Nicotine-Seeking Behavior Placebo control Yohimbine and Hydrocortisone Cigarette puff choices, working memory performance, anxiety levels

Ongoing Clinical Trials on Lactose Monohydrate

  • Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

    Recruiting

    3 1 1
    Investigated diseases:
    Germany
  • Evaluation of a Single Measurement Strategy for Direct Oral Anticoagulants in Frail Older Patients with Atrial Fibrillation or Venous Thromboembolism

    Recruiting

    3 1 1 1
    Investigated diseases:
    The Netherlands
  • Study on the Effects of Pseudoephedrine on Cycling Performance in Healthy Volunteers

    Recruiting

    3 1 1
    Belgium
  • Study on Early vs. Late Restart of Anticoagulation with Edoxaban, Apixaban, and Warfarin for Patients with Chronic Subdural Hematoma and Atrial Fibrillation

    Recruiting

    4 1 1 1
    Finland Sweden
  • Study on the Effects of Empagliflozin in Patients with Euvolemic and Hypervolemic Hyponatremia

    Recruiting

    2 1 1
    Germany The Netherlands
  • Study on the Effect of Clopidogrel and Acetylsalicylic Acid on Reducing Heart and Blood Vessel Events in Patients with Peripheral Arterial Disease

    Recruiting

    3 1 1
    The Netherlands
  • Study of acetylsalicylic acid to prevent stroke in patients undergoing brain aneurysm coiling procedure

    Recruiting

    3 1 1
    France
  • Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

    Recruiting

    3 1 1 1
    Investigated diseases:
    Austria Bulgaria Croatia France Germany Hungary +5
  • Study on Short-term Interruption vs. Continuous Anticoagulation with Apixaban in Patients Undergoing Colorectal Polypectomy

    Recruiting

    3 1 1 1
    Spain
  • Study on the Effect of Aprepitant on Aldosterone Levels in Patients with Obstructive Sleep Apnea and High Blood Pressure

    Recruiting

    3 1 1
    Investigated drugs:
    France

Glossary

  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a new drug or therapy. It helps researchers determine if the active treatment is more effective than no treatment at all.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the active treatment and who is receiving the placebo. This helps prevent bias in the results.
  • Randomized controlled trial: A type of clinical study where participants are randomly assigned to different treatment groups, including a placebo group, to compare the effects of various interventions.
  • Clinical outcome: A measurable change in health, function, or quality of life that results from a medical intervention or treatment.
  • Intervention: Any treatment, drug, or procedure being tested in a clinical trial to prevent, detect, or treat a medical condition.
  • Efficacy: The ability of a treatment or intervention to produce the desired beneficial effect under ideal conditions, such as in a controlled clinical trial.
  • Adverse event: Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.

References

  1. https://clinicaltrials.gov/study/NCT04894617
  2. https://clinicaltrials.gov/study/NCT03670212